11C-acetate for Treatment Response After Radiotherapy for HCC

Stopped early · Phase 2

Conditions studied: Hepatocellular Carcinoma

In brief

It is thought that PET of the abdomen with 11C Acetate will provide new information regarding whether or not patient's have benefited from radiotherapy. To test this theory, the project will evaluate the potential of 11C acetate to serve as an earlier and/or better signal of treatment success.

Key facts

Study ID

NCT02549755

Run by

Justin Sims

People needed

1

Starts

2015-09-01

Expected to finish

2016-10-01

Last updated by the study team

2017-11-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• > 18 years of age
• Subject is willing to participate in the study and has signed the study informed consent
• Subject is available and willing to comply with the protocol evaluations
• Diagnosed hepatocellular carcinoma confined to a single lobe of the liver if undergoing 90Y radioembolization
• Diagnosed hepatocellular carcinoma confined to the liver if undergoing Stereotactic Body Radiation Therapy (SBRT)
• Under consideration for 90Y radioembolization or Stereotactic Body Radiation Therapy (SBRT)

You may not qualify if…

• Pregnant or planning to become pregnant within the next 12 months or breast-feeding
• GFR < 45
• Life expectancy < 6 months
• Claustrophobic and cannot tolerate imaging procedures
• Weigh > 350 lb (upper weight limit of scanner beds)
• Special vulnerabilities (e.g. fetuses, neonatales, pregnant women, children, prisoners, institutionalized individuals).

Where it is running

• Indiana University — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.